The Bigger They Are, Less Prison Time They Serve

Posted July 19, 2012
What lesson can we learn from the $3 billion settlement paid by GlaxoSmithKline to the U.S. treasury? The lesson drug makers acquire from the settlement may surprise you. If you are like GSK and earn about $28 billion annually, you must realize that you can get away with promoting drugs for unapproved uses, including promoting unapproved uses for the antidepressants Paxil and Wellbutrin, and with concealing for seven years from the FDA evidence that the Type 2 diabetes drug Avandia substantially increases the risk of heart toxicity without ever suffering a serious loss of any kind.  Read more.

RSS